{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:48:39Z","timestamp":1789530519814,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["CASIMM0120234003"],"award-info":[{"award-number":["CASIMM0120234003"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SIMM0120231003"],"award-info":[{"award-number":["SIMM0120231003"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023279","name":"Alliance of International Science Organizations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20379"],"award-info":[{"award-number":["U22A20379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117004","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:17:40Z","timestamp":1730269060000},"page":"117004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2"],"prefix":"10.1016","volume":"281","author":[{"given":"Samuel Desta","family":"Guma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feipu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Mintah","family":"Bonku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullajon","family":"Odilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-4841","authenticated-orcid":false,"given":"Qiumeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117004_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1099\/0022-1317-83-3-595","article-title":"Conservation of substrate specificities among coronavirus main proteases","volume":"83","author":"Hegyi","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejmech.2024.117004_bib2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/med.21783","article-title":"What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design","volume":"41","author":"Xiong","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117004_bib3","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117004_bib4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117004_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117004_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2024.117004_bib7","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2024.117004_bib8","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1021\/acs.jmedchem.2c01005","article-title":"Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure-activity relationship insights and evolution perspectives","volume":"65","author":"La Monica","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/biom13091339","article-title":"Recent advances in SARS-CoV-2 main protease inhibitors: from nirmatrelvir to future perspectives","volume":"13","author":"Citarella","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2024.117004_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bbrc.2020.10.091","article-title":"The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2","volume":"538","author":"Jin","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.117004_bib11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117004_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1039\/D3MD00493G","article-title":"On the origins of SARS-CoV-2 main protease inhibitors","volume":"15","author":"Janin","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2024.117004_bib14","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib15","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117004_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41564-024-01618-9","article-title":"Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir","volume":"9","author":"Chen","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ejmech.2024.117004_bib17","first-page":"1","article-title":"Discovery of GST-hg171, A potent and selective oral 3CL protease inhibitor for the treatment of COVID-19, sm","volume":"6","author":"Zhang","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2024.117004_bib18","doi-asserted-by":"crossref","first-page":"JC63","DOI":"10.7326\/J22-0038","article-title":"In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death","volume":"175","author":"Vassilopoulos","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2024.117004_bib19","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ejmech.2024.117004_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102582","article-title":"Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"71","author":"Lu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejmech.2024.117004_bib21","first-page":"509","article-title":"Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy","volume":"29","author":"Igho-Osagie","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ejmech.2024.117004_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.117004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","volume":"91","author":"Ip","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.117004_bib25","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2024.117004_bib26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117004_bib27","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/S0960-894X(99)00368-6","article-title":"Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids","volume":"9","author":"Dragovich","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.117004_bib28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2024.117004_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17460441.2020.1733526","article-title":"An overview of spirooxindole as a promising scaffold for novel drug discovery","volume":"15","author":"Zhou","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117004_bib30","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.bmcl.2010.05.025","article-title":"One-pot multicomponent synthesis and anti-microbial evaluation of 2\u2032-(indol-3-yl)-2-oxospiro (indoline-3, 4\u2032-pyran) derivatives","volume":"20","author":"Nandakumar","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2024.117004_bib31","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1021\/jm201715d","article-title":"Discovery and optimization of a novel spiropyrrolidine inhibitor of \u03b2-secretase (BACE1) through fragment-based drug design","volume":"55","author":"Efremov","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911861","article-title":"Design, synthesis and in vitro evaluation of spirooxindole-based phenylsulfonyl moiety as a candidate anti-SAR-CoV-2 and MERS-CoV-2 with the Implementation of combination studies","volume":"23","author":"Barakat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.117004_bib33","series-title":"Novel Spiropyrrolidine Derived Antiviral Agents","author":"Wang","year":"2022"},{"key":"10.1016\/j.ejmech.2024.117004_bib34","series-title":"Novel Spiropyrrolidine Derived Antiviral Agents","author":"Wang","year":"2023"},{"key":"10.1016\/j.ejmech.2024.117004_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2024.117004_bib36","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib37","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1021\/jm060325b","volume":"49","author":"Venkatraman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114030","article-title":"Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19","volume":"228","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02013-21","article-title":"Structural basis of the main proteases of coronavirus bound to drug candidate PF-07321332","volume":"96","author":"Li","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2024.117004_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1039\/D2SC05473F","article-title":"Enantioselective inhibition of the SARS-CoV-2 main protease with rhenium(i) picolinic acid complexes","volume":"14","author":"Karges","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2024.117004_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115512","article-title":"Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2","volume":"257","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113863","article-title":"Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization","volume":"226","author":"Di Sarno","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib43","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1038\/s41467-023-42527-5","article-title":"Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117004_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116128","article-title":"Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: in silico design, synthesis and pharmacological characterization","volume":"266","author":"Ciaglia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117004_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.117004_bib46","article-title":"MPI8 is potent against SARS-CoV-2 by inhibiting dually and selectively the SARS-CoV-2 main protease and the host cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117004_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2024.117004_bib48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2024.117004_bib49","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J. Chem. Inf. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424008869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424008869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:56:25Z","timestamp":1734252985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424008869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"alternative-id":["S0223523424008869"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117004","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of peptidomimetic spiropyrrolidine derivatives as novel 3CLpro inhibitors against SARS-CoV -2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117004"}}